Knight Therapeutics Inc (GUD):企業の財務・戦略的SWOT分析

◆英語タイトル:Knight Therapeutics Inc (GUD) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH511336FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Knight Therapeutics Inc (Knight Therapeutics) focuses on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. The company offers tablets to treat metabolic, renal diseases and cancer; and injections against chronic pain and hormone dependent advanced carcinoma of the prostate gland. It also supplies implants for the treatment of diabetic macular edema (DME). Knight Therapeutics is investigating drugs targeting acute migraine, pain, inflammation, human papillomavirus associated cancers, hyperphosphatemia and neurological disorders. The company seeks to work in partnership with pharmaceutical and biotechnology companies to develop its products. Knight Therapeutics is headquartered in Montreal, Quebec, Canada.

Knight Therapeutics Inc Key Recent Developments

Mar 25,2021: Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results
Mar 18,2021: Notice of Knight Therapeutics’ Fourth Quarter 2020 Results Conference Call
Mar 01,2021: Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ – New Innovative Treatment for Irritable Bowel Syndrome with Constipation
Jan 22,2021: Crescita secures line of credit with the Royal Bank of Canada following repayment in full of Knight Therapeutics loan
Nov 13,2020: Knight Therapeutics reports third quarter 2020 results

This comprehensive SWOT profile of Knight Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Knight Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Knight Therapeutics Inc – Key Information
Knight Therapeutics Inc – Overview
Knight Therapeutics Inc – Key Employees
Knight Therapeutics Inc – Key Employee Biographies
Knight Therapeutics Inc – Key Operational Heads
Knight Therapeutics Inc – Major Products and Services
Knight Therapeutics Inc – History
Knight Therapeutics Inc – Company Statement
Knight Therapeutics Inc – Locations And Subsidiaries
Knight Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Knight Therapeutics Inc – Business Description
Knight Therapeutics Inc – Corporate Strategy
Knight Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Knight Therapeutics Inc – Strengths
Knight Therapeutics Inc – Weaknesses
Knight Therapeutics Inc – Opportunities
Knight Therapeutics Inc – Threats
Knight Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Knight Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Knight Therapeutics Inc, Key Information
Knight Therapeutics Inc, Key Ratios
Knight Therapeutics Inc, Share Data
Knight Therapeutics Inc, Major Products and Services
Knight Therapeutics Inc, History
Knight Therapeutics Inc, Key Employees
Knight Therapeutics Inc, Key Employee Biographies
Knight Therapeutics Inc, Key Operational Heads
Knight Therapeutics Inc, Other Locations
Knight Therapeutics Inc, Subsidiaries
Knight Therapeutics Inc, Key Competitors
Knight Therapeutics Inc, SWOT Analysis
Knight Therapeutics Inc, Ratios based on current share price
Knight Therapeutics Inc, Annual Ratios
Knight Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Knight Therapeutics Inc (GUD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kraftwerke Oberhasli AG:企業の戦略的SWOT分析
    Kraftwerke Oberhasli AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Cathay Pacific Airways Limited:企業のM&A・事業提携・投資動向
    Cathay Pacific Airways Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cathay Pacific Airways Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Harmonic Inc (HLIT):企業の財務・戦略的SWOT分析
    Harmonic Inc (HLIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hannover Ruck SE:企業の戦略・SWOT・財務情報
    Hannover Ruck SE - Strategy, SWOT and Corporate Finance Report Summary Hannover Ruck SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Mauritius Commercial Bank Limited:企業の戦略・SWOT・財務分析
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Intercept Pharmaceuticals Inc (ICPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid ( …
  • Greene King PLC:企業の戦略・SWOT・財務情報
    Greene King PLC - Strategy, SWOT and Corporate Finance Report Summary Greene King PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SOCOMEC Group:企業の戦略的SWOT分析
    SOCOMEC Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Sabine Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Sabine Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Sabine Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive informat …
  • Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process include …
  • Ferrovial, S.A.:企業の戦略・SWOT・財務情報
    Ferrovial, S.A. - Strategy, SWOT and Corporate Finance Report Summary Ferrovial, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Pinnacle West Capital Corporation:企業の戦略・SWOT・財務分析
    Pinnacle West Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Pinnacle West Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Commonwealth Bank of Australia:企業のM&A・事業提携・投資動向
    Commonwealth Bank of Australia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Commonwealth Bank of Australia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Gerresheimer AG:戦略・SWOT・企業財務分析
    Gerresheimer AG - Strategy, SWOT and Corporate Finance Report Summary Gerresheimer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hydrogenics Corporation (HYG)-エネルギー分野:企業M&A・提携分析
    Summary Hydrogenics Corporation (Hydrogenics) is a provider of power generation equipment. It designs, develops, and manufactures hydrogen generation, energy storage, and fuel cell products. The company produces products on water electrolysis technology and proton exchange membrane (PEM) technology. …
  • Alfa SAB de CV (ALFAA):石油・ガス:M&Aディール及び事業提携情報
    Summary Alfa SAB de CV (Alfa) is a diversified company that operates in the petrochemical, refrigerated food, lightweight solutions, telecommunication, and oil and gas sectors. Alfa develops and manufactures high technology aluminum components for the power train and body structure of automotive. It …
  • Petrobras Argentina SA:企業の戦略的SWOT分析
    Petrobras Argentina SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ovensa Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ovensa Inc (Ovensa) is a preclinical stage company that develops nanotherapeutics. The company uses its proprietary Triozan Nanomedicine delivery platform that has mucosal and brain-barrier crossing properties used in treatment of oncology and neurodegenerative diseases. Its Triozan helps in …
  • Indianapolis Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Indianapolis Power & Light Co (IPL), a subsidiary of IPALCO Enterprises Inc, is an integrated electric utility. The company generates, transmits, distributes, and sells electric energy. It produces electricity from coal, oil, and natural gas sources. IPL owns and operates power plants in Ind …
  • Penumbra Inc (PEN):医療機器:M&Aディール及び事業提携情報
    Summary Penumbra Inc (Penumbra) is a medical device company that designs, develops, manufactures and markets neuro devices and peripheral devices. The company’s neurovascular mechanical thrombectomy systems include revascularization device, reperfusion catheters, distal delivery catheters, neuro eva …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆